Bluejay Diagnostics is a medical devices business based in the US. Bluejay Diagnostics shares (BJDX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.09 – a decrease of 13.76% over the previous week. Bluejay Diagnostics employs 10 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.09 |
|---|---|
| 52-week range | $0.10 - $38.96 |
| 50-day moving average | $0.20 |
| 200-day moving average | $3.64 |
| Wall St. target price | $256.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-43.04 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.094 from 2024-10-18
| 1 week (2024-10-14) | -13.76% |
|---|---|
| 1 month (2024-09-20) | -33.80% |
| 3 months (2024-07-19) | -85.00% |
| 6 months (2024-04-19) | -82.91% |
| 1 year (2023-10-20) | -97.65% |
|---|---|
| 2 years (2022-10-21) | -88.94% |
| 3 years (2021-10-17) | N/A |
| 5 years (2019-10-17) | N/A |
| Gross profit TTM | $48,911 |
|---|---|
| Return on assets TTM | -58.51% |
| Return on equity TTM | -125.25% |
| Profit margin | 0% |
| Book value | $3.34 |
| Market Capitalization | $1.9 million |
TTM: trailing 12 months
We're not expecting Bluejay Diagnostics to pay a dividend over the next 12 months.
You may also wish to consider:
Bluejay Diagnostics's shares were split on a 1:8 basis on 19 June 2024 . So if you had owned 8 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Bluejay Diagnostics shares – just the quantity. However, indirectly, the new 700% higher share price could have impacted the market appetite for Bluejay Diagnostics shares which in turn could have impacted Bluejay Diagnostics's share price.
Over the last 12 months, Bluejay Diagnostics's shares have ranged in value from as little as $0.1042 up to $38.96. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bluejay Diagnostics's is 0.698. This would suggest that Bluejay Diagnostics's shares are less volatile than average (for this exchange).
To put Bluejay Diagnostics's beta into context you can compare it against those of similar companies.
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. The company offers Symphony platform, a technology platform comprising Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. It also provides ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, the company develops Symphony IL-6 test for the monitoring of disease progression in critical care settings. Further, it develops cardiac biomarkers, such as hsTNT and NT pro-BNP, as well as other tests using the Symphony platform. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
What you need to know about investing in the leading indicator for the overall US stock market.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Read our beginner’s guide to trading options in the US.